Last reviewed · How we verify

creon 35.000 Ph.U (R)

Hospital Clinico Universitario de Santiago · FDA-approved active Small molecule

creon 35.000 Ph.U (R) is a Pancreatic enzyme replacement therapy Small molecule drug developed by Hospital Clinico Universitario de Santiago. It is currently FDA-approved for Pancreatic insufficiency due to cystic fibrosis, Pancreatic insufficiency due to chronic pancreatitis, Pancreatic insufficiency following pancreatic surgery.

Creon is a pancreatic enzyme replacement therapy that supplies lipase, amylase, and protease to aid digestion of fats, carbohydrates, and proteins in patients with pancreatic insufficiency.

Creon is a pancreatic enzyme replacement therapy that supplies lipase, amylase, and protease to aid digestion of fats, carbohydrates, and proteins in patients with pancreatic insufficiency. Used for Pancreatic insufficiency due to cystic fibrosis, Pancreatic insufficiency due to chronic pancreatitis, Pancreatic insufficiency following pancreatic surgery.

At a glance

Generic namecreon 35.000 Ph.U (R)
SponsorHospital Clinico Universitario de Santiago
Drug classPancreatic enzyme replacement therapy
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

Creon contains pancreatic enzymes derived from porcine pancreas that are enteric-coated to survive stomach acid and release in the small intestine. These enzymes compensate for insufficient endogenous pancreatic enzyme production, enabling proper breakdown and absorption of dietary macronutrients in patients with conditions causing pancreatic insufficiency.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about creon 35.000 Ph.U (R)

What is creon 35.000 Ph.U (R)?

creon 35.000 Ph.U (R) is a Pancreatic enzyme replacement therapy drug developed by Hospital Clinico Universitario de Santiago, indicated for Pancreatic insufficiency due to cystic fibrosis, Pancreatic insufficiency due to chronic pancreatitis, Pancreatic insufficiency following pancreatic surgery.

How does creon 35.000 Ph.U (R) work?

Creon is a pancreatic enzyme replacement therapy that supplies lipase, amylase, and protease to aid digestion of fats, carbohydrates, and proteins in patients with pancreatic insufficiency.

What is creon 35.000 Ph.U (R) used for?

creon 35.000 Ph.U (R) is indicated for Pancreatic insufficiency due to cystic fibrosis, Pancreatic insufficiency due to chronic pancreatitis, Pancreatic insufficiency following pancreatic surgery.

Who makes creon 35.000 Ph.U (R)?

creon 35.000 Ph.U (R) is developed and marketed by Hospital Clinico Universitario de Santiago (see full Hospital Clinico Universitario de Santiago pipeline at /company/hospital-clinico-universitario-de-santiago).

What drug class is creon 35.000 Ph.U (R) in?

creon 35.000 Ph.U (R) belongs to the Pancreatic enzyme replacement therapy class. See all Pancreatic enzyme replacement therapy drugs at /class/pancreatic-enzyme-replacement-therapy.

What development phase is creon 35.000 Ph.U (R) in?

creon 35.000 Ph.U (R) is FDA-approved (marketed).

What are the side effects of creon 35.000 Ph.U (R)?

Common side effects of creon 35.000 Ph.U (R) include Abdominal pain, Diarrhea, Nausea, Constipation, Fibrosing colonopathy (rare, high-dose).

Related